AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. - Wikidata - awgldk - TriplyDB

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

http://www.wikidata.org/entity/Q34464133

about

HIV Genome-Wide Protein Associations: a Review of 30 Years of Research Harnessing the protective potential of HIV-1 neutralizing antibodies Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors Emerging Vaccine Technologies Engineering humoral immunity as prophylaxis or therapy Bone Marrow Gene Therapy for HIV/AIDS HIV therapeutic vaccines: moving towards a functional cure Structure and Dynamics of the Native HIV-1 Env Trimer AAV-Delivered Antibody Mediates Significant Protective Effects against SIVmac239 Challenge in the Absence of Neutralizing Activity New concepts in HIV-1 vaccine development Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus Meeting Report: The Allied Genetics Conference 2016 A second-generation expression system for tyrosine-sulfated proteins and its application in crop protection A Little Help From the Follicles: Understanding the Germinal Center Response to Human Immunodeficiency Virus 1 Infection and Prophylactic Vaccines.Sulfotyrosine dipeptide: Synthesis and evaluation as HIV-entry inhibitor.Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.Gene Therapy 2017: Progress and Future Directions.A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors.Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.AAV's Golden Jubilee.Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.Malaria. A forward genetic screen identifies erythrocyte CD55 as essential for Plasmodium falciparum invasion.Functional Mimetics of the HIV-1 CCR5 Co-Receptor Displayed on the Surface of Magnetic Liposomes.Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection.Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.BLT humanized mice as a small animal model of HIV infection.A new hypothesis on HIV cure.Recombinant AAV Vectors for Enhanced Expression of Authentic IgG.Envelope Glycoprotein Internalization Protects Human and Simian Immunodeficiency Virus-Infected Cells from Antibody-Dependent Cell-Mediated Cytotoxicity.Dose-response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies The rice immune receptor XA21 recognizes a tyrosine-sulfated protein from a Gram-negative bacterium.Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization.Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys Preparation and Analysis of N-Terminal Chemokine Receptor Sulfopeptides Using Tyrosylprotein Sulfotransferase Enzymes.Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques

P2860

Q26746070-FE3A1703-2575-4FEC-BCDB-1D5A8A88C000 Q26766153-D0B83337-FE63-4C9C-9F39-5831F2214158 Q26777448-5EC3743C-0751-4A9C-8743-9DFBD5C5D973 Q26783764-96623F04-1193-4329-A18D-F2951BC9016D Q26800101-0A0E01B0-28B1-4C10-B61A-D1B0D6D42600 Q26801765-FA2A4703-F213-48FE-9B66-0F7B3A790802 Q27002180-FF28D90A-867D-49E9-8414-DC2FC99C02A6 Q27027570-E86531CF-C29C-4848-B95B-DF72F9E50213 Q27318266-AF8C7777-F4E0-42E6-9146-0A33A91ED5F3 Q28067027-06CC6F28-A5F4-4631-BDDC-7341B3444095 Q28068946-394C2683-10EC-4F92-BCEF-13F9400740E2 Q28551914-5A4F88E9-1290-47A0-8475-F45B73100D66 Q28588672-0F9E30B1-D642-4630-B6BD-394825F7728C Q28822174-F3763ACE-9696-4D30-BFCB-20D811AB69EB Q30234577-F6D85C1D-3970-42C1-8835-23F8807CC412 Q30391222-3C439F9C-41D4-4922-9EE6-8CD9D5280E31 Q30490945-B4FA2B1D-EF0F-4C49-BB8A-0F3C4392DCC9 Q33592852-8DD5F0DA-A11C-489A-8945-DCE970AE8B7B Q33620546-8138980A-EC00-4769-B44E-AF2F9E0CAAC5 Q33654409-EBD76D23-53F7-46CA-81D3-9B38362F135B Q33891559-53A9F52D-9EF4-411D-9762-BBD1A6A43552 Q33906477-8DA26A7C-D25C-46BC-A676-043CA12B93FD Q34531219-E132B284-5E17-438B-BD5D-FED7FC03EA60 Q35594880-2141263C-6056-44EC-A7DD-B59E6F665EE0 Q35677620-1356B463-0DE8-41E9-90DF-2BFF87608E73 Q35736368-D1A167E1-66A0-4D2D-8ED5-6CCC10E76829 Q35858649-872C7C3E-DB18-4648-AA62-D91C19975F42 Q35914292-B6C86B69-ED03-4587-93A3-C45D82D48CEE Q35952586-49C24B01-A8E4-4EC1-AFE3-088D86C05FFF Q35998374-DED013CE-5BC4-4503-837C-56327E55898C Q36028475-78A0FAA8-3FF3-4EC1-825E-982314DC22D6 Q36058890-0E3D992C-49E0-4C7F-BD18-461833A19560 Q36086204-BE5CA674-B519-4EA3-930A-C39E11B25C08 Q36105672-E71B73D7-2B4E-43AB-8DD0-4F2C186EE274 Q36284778-A146A9FA-9154-4DEA-BA43-44176AE35B70 Q36298503-A1FB1558-DF6D-4677-9FA3-EE3C5462DFF1 Q36334359-BBC142DB-5923-4FDB-9C65-D04AA7C3888B Q36582838-E4E20AC9-87E8-488B-8A68-3CBC1BD759DC Q36756930-C0088AB9-52F1-45B0-8337-46BC7EEC7052 Q37021717-BCB4E25E-B476-4A8D-B059-4F12AF226886

P2860

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

http://www.wikidata.org/entity/Q34464133

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@ast

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@en

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@nl

type

label

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@ast

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@en

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@nl

prefLabel

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@ast

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@en

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@nl

P1433

Q34464133-6997929E-EE38-4D56-8F61-9E905643230F

P1476

Q34464133-1A3EC20D-5493-409F-8B53-DE325E4895C7

P2093

Q34464133-25E7E884-DC35-4BA7-B252-9BB4D2170755

Q34464133-3A03EE4D-E6B8-4F9B-9912-2949925E268C

Q34464133-3B7EA3C5-0D4B-4417-A6A9-36E7AA19963E

Q34464133-3E7FE744-0CC8-4576-956F-BE4CE0FC59FD

Q34464133-53F9933C-9FC3-4637-9C2B-64FFB1F41518

Q34464133-5C6A8AFE-ABF4-4DCB-9DBF-B89F9C853F7C

Q34464133-6297BDCB-B8B9-492F-8ECE-6986A30278E1

Q34464133-640132F2-7CB1-4E3F-9D64-CA5F2128EAF8

Q34464133-6FE6C3A8-789B-4F35-98E0-A9F0AF6A670D

Q34464133-707D62B7-CD4F-4FA3-A0C5-CDBEE452D7EE

P2860

Q34464133-007EE6AB-044F-41D1-B57F-71775451BC14

Q34464133-04202DD8-D287-422B-829B-A43AC59C2A32

Q34464133-055B7CC7-DB1E-43BB-9482-7C3CF6B659C5

Q34464133-08241E76-7B6F-47F0-A957-388E7D45F0B9

Q34464133-0D64630A-E257-4D9E-BA2A-6F985E1F1D8F

Q34464133-1C419E6F-5C7C-46B5-86B8-2302F1F09CD5

Q34464133-27F3D856-1DB8-4142-9303-8D4125B8C979

Q34464133-2A96BDBA-5134-4FF3-AED1-866782396FC1

Q34464133-36F2D04A-20C9-4F10-BE28-709563303CCA

Q34464133-3707A6B3-0885-4B54-A97C-96B0A1F00338

P2888

Q34464133-E1247423-0675-42EA-937D-944102DAC520

P304

Q34464133-3DC1B251-E99A-45F9-8F26-CB6FFA8144DD

P31

Q34464133-34FFEF14-C6DA-4697-8FDA-BC6AABCB8D92

P356

Q34464133-B907D843-6991-49FD-AC1C-04C1AF2A90C2

P407

Q34464133-E05C2497-CAF6-472B-9589-C5DD7A01734C

P433

Q34464133-E1767A78-60D0-486C-BB38-53E1D2AFA7F9

P478

Q34464133-8E8457B8-A9F7-4E60-8768-F8D3D4B4DA04

P50

Q34464133-3F7ED433-B6DB-4F07-B87B-3B14257C2EEE

Q34464133-6A474993-CDE9-436A-B633-C6E3292CFDAC

Q34464133-8448CACE-FF7F-4B78-97CE-1754050FF155

Q34464133-9CDC7FD5-6B21-4F65-94D6-40B3D9488324

Q34464133-B8755606-6908-414A-A130-936A3CB524DA

Q34464133-D6BAB903-9C51-4D42-B5F0-F84EC7348696

Q34464133-DA3F5094-931D-4B4C-8F3C-1CE136F2EFB0

P577

Q34464133-D997171B-A0B8-4C79-8103-A1DB5989F03F

P5875

Q34464133-4A160294-0502-46CA-B767-53F3BD59CB7C

P698

Q34464133-378C4EE4-40B4-4776-A40E-AD60D900A12A

P932

Q34464133-D991264E-D8C2-4E65-A8DD-CE1D777A80F3

P356

P1433

P1476

AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.

@en

P2093

Alexander Ploss

http://www.w3.org/2001/XMLSchema#string

Annie Y Yao

http://www.w3.org/2001/XMLSchema#string

Baoshan Zhang

http://www.w3.org/2001/XMLSchema#string

Charles C Bailey

http://www.w3.org/2001/XMLSchema#string

David T Evans

http://www.w3.org/2001/XMLSchema#string

Dennis R Burton

http://www.w3.org/2001/XMLSchema#string

Ernest S Neale

http://www.w3.org/2001/XMLSchema#string

Guangping Gao

http://www.w3.org/2001/XMLSchema#string

Hema R Kondur

http://www.w3.org/2001/XMLSchema#string

Hugo Mouquet

http://www.w3.org/2001/XMLSchema#string

P2860

Structural mechanism of trimeric HIV-1 envelope glycoprotein activation

Increasing the potency and breadth of an HIV antibody by using structure-based rational design

Identification of gammaretroviruses constitutively released from cell lines used for human immunodeficiency virus research

Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1-infected children

Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity

ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge

Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120

Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

P2888

P304

87-91

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE14264

http://www.w3.org/2001/XMLSchema#string

P407

P433

7541

http://www.w3.org/2001/XMLSchema#string

P478

519

http://www.w3.org/2001/XMLSchema#string

P50

Michel C. Nussenzweig

Beatrice H. Hahn

Christoph H Fellinger

Pascal Poignard

Brian D Quinlan

P577

2015-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272844098

http://www.w3.org/2001/XMLSchema#string

P698

25707797

http://www.w3.org/2001/XMLSchema#string

P932

4352131

http://www.w3.org/2001/XMLSchema#string